How to Avoid Desk Rejection at JAMA

JAMA editors are making a consequence judgment long before they are making a detailed methods judgment. They want to know four things fast.

• Who cares? Will a broad physician audience care, not just one department or subspecialty?

• What changes? Does this paper change care, interpretation, policy, screening, risk framing, or another real medical decision?

• How hard is it to trust? Does the design look sturdy enough to survive rapid scrutiny?

• Is the payoff obvious? Can the importance be understood from the title and abstract without reading the paper like a methods reviewer?

If the paper looks narrow, soft-ended, or overstated, the triage decision can happen very quickly.

In our pre-submission review work with manuscripts targeting JAMA, we have found that the biggest desk-rejection risk is usually not basic quality. It is audience mismatch plus overclaimed consequence.

The study is strong, but the readership is wrong. We have found that many manuscripts are excellent specialty papers that are being asked to function as general-medicine papers. Editors specifically screen for whether the argument still matters after the specialty framing is stripped away.

The endpoint is too far from a real decision. Our analysis of borderline JAMA submissions is that surrogate-heavy or technically interesting outcomes often fail when the manuscript cannot explain what a broad physician should do differently.

The abstract sounds bigger than the paper. Editors specifically screen for abstracts that promise practice change while the figures only support a narrower conclusion.

The methods look exposed to predictable reviewer skepticism. Fragile observational logic, subgroup-heavy interpretation, or thin causal framing can make a manuscript look expensive to send out, even when the topic is important.

• the question is broad enough for general medicine, not only a specialty service line
• the primary outcome matters directly to patient care or physician decision-making
• the methods look sturdy enough that reviewer skepticism will focus on interpretation, not repair
• the abstract explains the practical consequence without insider shorthand
• the discussion stays proportionate to the actual strength of the data
• the journal choice is driven by readership fit rather than by brand aspiration

• This is the most common problem.
• A paper can be excellent and still be a better fit for JAMA Oncology, Circulation, Clinical Infectious Diseases, or another field-leading venue.
• General medicine is not the same thing as high prestige.
• It is a different audience test.

• JAMA responds much better to outcomes that affect actual clinical decisions than to papers built on soft surrogates, intermediate biomarkers, or abstract model logic.
• If the endpoint matters only after several layers of interpretation, the paper feels weaker for a broad medical journal.

• Editors know which designs invite immediate reviewer doubt.
• Fragile subgroup stories, thin causal logic, unclear confounding control, and heavy reliance on retrospective convenience data all make a manuscript feel expensive to review.
• JAMA does publish observational work.
• But it needs to look unusually disciplined.

• A lot of papers lose altitude because the first page assumes the reader already lives in the disease area.
• JAMA abstracts need to work for physicians who are smart but not embedded in your specialty vocabulary.

• Editors at this level can spot inflated clinical framing quickly.
• If the paper sounds practice-changing but the data still feel modest, trust falls.
• JAMA is far more receptive to crisp, earned claims than to ambitious interpretation.

• Some studies answer useful questions that matter deeply to one community.
• That alone does not make them JAMA papers.
• The journal wants questions that travel across general medical readership, not only across one disease niche.

The best JAMA submissions usually feel easy to explain in plain language. That simplicity is not a sign of weak science. It is a sign that the paper knows exactly which decision it changes.

• The title names the clinical issue clearly.
• The abstract gets to the consequence early.
• The primary outcome feels worth a general physician's attention.
• The methods look hard to dismiss on first inspection.
• The discussion sounds measured enough that editors trust it.

If your paper is hard to summarize without a paragraph of specialty context, it is already at a disadvantage.

A rough rule helps here. Papers tend to travel when they clarify a decision that many physicians recognize already. They tend not to travel when they answer a narrower technical question that mostly matters after a specialist translates it.

• More likely to travel: treatment comparisons, practice implications, large risk questions, screening decisions, high-authority safety findings.

• Less likely to travel: narrow mechanistic correlates, specialty workflow tweaks, surrogate-heavy analyses with weak patient consequence, or papers whose main value is to one clinical niche.

That does not make the second group weak science. It just means the readership fit is different. Authors lose time when they use JAMA as a prestige test instead of an audience test.

One more useful check is to hand the title and abstract to a physician outside the specialty and ask what the paper changes. If the answer comes back as "interesting, but mostly for that field," the editor may feel the same thing. JAMA rewards manuscripts that survive that test cleanly.

Before you submit, answer these questions bluntly.

• Decision test: what exact clinical decision becomes clearer because of this paper?

• Audience test: would a hospitalist, internist, or general clinician care even if this is not their main field?

• Endpoint test: are the outcomes close enough to patient care to feel meaningful without translation?

• Credibility test: what is the first methods attack an editor would expect reviewers to make?

• Fit test: are you choosing JAMA because the readership fits, or because the brand is tempting?

If those answers feel wobbly, the journal choice is probably wobbly too.

• Rewrite the abstract for broad physicians rather than specialists.
• Lead with the endpoint that matters most to care, not the most statistically complex endpoint.
• Cut field-specific framing that narrows perceived audience.
• Make the methods credibility visible early. Do not hide the hardest design question.
• Lower any sentence that implies practice change unless the data truly carry that weight.
• Make the first page answer, in plain language, why this matters to general medicine now.

The cover letter should make one clean case: why this manuscript belongs in a broad medical journal now. Not why the disease is important in general. Not why the field cares. Why a wide physician readership should spend time on this paper now.

If that case turns fuzzy as you write it, the submission is telling you something useful.

If the natural reader is still one specialty group, a top field journal is often the smarter first move. If the endpoint is indirect, the design still looks exposed, or the implication is more technical than broadly clinical, JAMA may cost you time without giving you a real shot.

• the paper changes a real general-medicine decision
• the outcome matters without specialist translation
• the methods look sturdy on first read
• the abstract explains the payoff quickly
• the audience is broader than one specialty service
• the paper fits JAMA because of readership, not only prestige

To avoid desk rejection at JAMA, make the paper feel broadly clinical, methodologically sturdy, and immediately useful to general medicine. If the real audience is still one specialty, the editor will feel that before review starts.

A JAMA desk-rejection risk check can flag the desk-rejection triggers covered above before your paper reaches the editor.

For adjacent fit checks, compare JAMA journal overview, JAMA impact factor, How to choose the right journal, and the Pre-submission checklist.